Paper · 27363387

Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

Perera M and 7 others. Eur Urol, 2016. Cited by 825 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Papers, record 27363387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27363387

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.; PubMed
Journal: Eur Urol; PubMed
Year: 2016; PubMed
Publication types: Journal Article, Meta-Analysis, Systematic Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/27363387/; PubMed
DOI: https://doi.org/10.1016/j.eururo.2016.06.021; PubMed
The journal: https://conductscience.org/library/journal-index/7512719; PubMed
Citations, by iCite: 825; iCite
Relative citation ratio, by iCite: 33.1; iCite
Revised in PubMed: 2025-06-26; PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Perera M	Marlon
2	Papa N	Nathan
3	Christidis D	Daniel
4	Wetherell D	David
5	Hofman MS	Michael S
6	Murphy DG	Declan G
7	Bolton D	Damien
8	Lawrentschuk N	Nathan

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Prostatic Neoplasms	Major topic
Edetic Acid
Gallium Isotopes
Gallium Radioisotopes
Humans
Male
Oligopeptides
Positron-Emission Tomography
Sensitivity and Specificity

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Source
NCT03537391	Novel Imaging in Staging of Primary Prostate Cancer	Background	ClinicalTrials.gov
NCT04854369	68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)	Background	ClinicalTrials.gov
NCT05622162	Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7	Results	ClinicalTrials.gov
NCT07455097	COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)	Background	ClinicalTrials.gov

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers	Source
Comment in	27,481,174	68Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions?	https://conductscience.org/library/papers/27481174	PubMed
Comment in	27,591,933	Re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-37.	https://conductscience.org/library/papers/27591933	PubMed
Comment in	27,597,236	Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-37.	https://conductscience.org/library/papers/27597236	PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by457

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 825 citations.

PMID	Title	Journal	Year	In Papers	Source
42,944,960	Early Detection of Prostate Cancer: Advances in Screening, Biomarkers, and Imaging Strategies.	Curr Oncol Rep	2026	https://conductscience.org/library/papers/42944960	PubMed
42,918,868	Cancer theranostics.	Nat Rev Cancer	2026	https://conductscience.org/library/papers/42918868	PubMed
42,900,888	Theranostics for prostate cancer: A Canadian multidisciplinary expert report.	Can Urol Assoc J	2026	https://conductscience.org/library/papers/42900888	PubMed
42,799,856	Is early imaging a pitfall? Effect of [⁶⁸Ga]Ga-PSMA PET/CT timing after biopsy on SUVmax and adverse pathology prediction in low-to-intermediate risk prostate cancer.	Ann Nucl Med	2026	https://conductscience.org/library/papers/42799856	PubMed
42,733,591	Radiomics for Differentiating Prostate-Specific Membrane Antigen (PSMA)-Positive and PSMA-Negative Lymph Nodes in Prostate Cancer: An Exploratory 68Ga-PSMA PET-CT Study.	Cureus	2026	https://conductscience.org/library/papers/42733591	PubMed
42,698,629	The role of molecular profiling for castration-resistant prostate cancer treatment and therapy development.	Front Cell Dev Biol	2026	https://conductscience.org/library/papers/42698629	PubMed
42,693,211	PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis.	Eur J Nucl Med Mol Imaging	2026	https://conductscience.org/library/papers/42693211	PubMed
42,533,777	[18F]PSMA-1007 PET-Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer.	Int J Urol	2026	https://conductscience.org/library/papers/42533777	PubMed
42,489,991	Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.	Ann Surg Oncol	2026	https://conductscience.org/library/papers/42489991	PubMed
42,488,734	Magnetic resonance imaging-guided salvage high-dose-rate brachytherapy for local recurrence after prostatectomy and external beam radiotherapy.	J Contemp Brachytherapy	2026	https://conductscience.org/library/papers/42488734	PubMed

1 to 10 of 457

See all 457 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
KLK3	354	PubTator's text mining	https://conductscience.org/library/genes/354

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27363387

GET https://conductscience.org/api/papers/v1/27363387/cited_by?page=2

API reference For AI assistants